Application of LINC00963-related carcinogenic axis in early diagnosis and treatment of distant metastasis of prostate cancer

• Main Authors: ZHANG JIE, MU XINGYU, LIU ZHIHONG, WANG XIANG, ZHOU WENJIE, WANG XINYI, WU KE, YAO ZHIXIAN, SUN FENG, ZHENG JUNHUA, GAN TIAN, ZHENG ZHONG, LI MINGQING, ZHENG XINYI, LIU YUTONG
• Format: Patent
• Language: Chinese; English
• Published: 11.09.2020
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The invention relates to application of an LINC00963-related carcinogenic axis in early diagnosis and treatment of distant metastasis of prostate cancer. According to application of the LINC00963-related carcinogenic axis in early diagnosis and treatment of distant metastasis of prostate cancer, it is found through research that long non-coding RNA-LINC00963 is highly up-regulated in CRPC tissue,CRPC patients have poor prognosis, migration in vitro of PCa cells and migration in vivo of the PCa cells are promoted, through a combination of LINC00963 and miR-542-3p, the process that NOP2 servesas an inducer of migration of the PCa is promoted, the LINC00963/miR-542-3p/NOP2 is the carcinogenic axis, and the axis has potential for diagnosis and treatment of advanced PCa. 本发明涉及LINC00963相关致癌轴在前列腺癌远处转移的早期诊断和治疗中的应用。本发明研究发现，长的非编码RNA-LINC00963在CRPC组织中高度上调，并伴有不良预后，促进了PCa细胞的体外迁移及其在体内的转移，LINC00963通过与miR-542-3p结合从而促进NOP2充当PCa转移的诱导剂，LINC00963/miR-542-3p/NOP2是致癌轴，该轴具有晚期PCa的诊断和治疗潜力。